2nd Educational Webinar:
Everything you always wanted to know about Developing Drugs for Children with Cancer* (*But were afraid to ask)
29 June 2021 (5-6pm CET)
After the success of the 1st Educational Webinar on drug development in paediatric oncology, ACCELERATE is back with an exciting 2nd episode in the Webinar series “Everything you always wanted to know about Developing Drugs for Children with Cancer* (*But were afraid to ask)” on 29 June!
The focus of the 2nd episode will be Orphan Drug Regulations
- How does the orphan medicines regulation work in EU, US and Japan?
- How did it impact the field of rare diseases? What are the issues now in Research & Development?
- The oncology paradox: Why did the current adult-based approach not work for childhood cancers? How can we improve the situation to better target the ‘young patients’ needs?
- And much more…
We are all about the interaction experience: You will be able to engage with us via live polls, Q&A and to exchange with our best experts!
We will challenge you again with a difficult clinical research case. In fact, we will look at what happened to Nefario Pharmaceuticals and its Minionblastoma drug development since our LAST WEBINAR 😉
All stakeholders are welcome to join and participate!
When? 29th of June 2021, 5pm-6pm CEST
Register via the REGISTRATION button! Attendance is open and free for all!
Information, slides and video’s will be shared with you after the event.
About ACCELERATE’s Educational Webinar Series
Paediatric oncology drug development is a highly complex and ever evolving field, particularly regarding its regulatory framework. ACCELERATE’s Webinar Series will make it more understandable for all people involved in paediatric oncology
WHAT? Educational Webinars run by multi-stakeholder experts will explain complex topics in interactive, 1-hour sessions
WHEN? Throughout 2021
WHY? To foster and disseminate expertise in the paediatric oncology community by using ACCELERATE’s prominent position as an international, multi-stakeholder platform. These sessions will be of interests to researchers, students, fellows, pharma representatives, patient advocates and regulators
For more information contact: email@example.com